Pay in 4 interest-free payments of $6.84 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
Single agent, canfosfamide (C, TLK286) vs pegylated liposomal doxorubicin (D) or topotecan (T) in 3rd-line treatment of platinum (P) refractory or resistant ovarian cancer (OC): phase 3 study results [Abstract]
A total of 33 miRNAs were predicted to target G6PD in at least two of four independent programs employed in the current study
Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China)
Key Consumer and Product Trends Consumer preferences are shifting towards more sophisticated and transparent product offerings
US$ 21.05
US$ 27.39
US$ 22.00
US$ 28.29
